New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Global ETF Survey 2026
00678

CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF

The 00678 Exchange Traded Fund (ETF) is provided by Capital Investment Trust Corporation. It is built to track an index: NASDAQ Biotechnology Index. The 00678 ETF provides physical exposure, so by buying it you actually own parts of all the 253 underlying holdings. The dividend policy is capitalization.

Advertisement

Advertisement

NT$40.52
-NT$0.2 (-0.49%) today
1:00 AM 07/14/26 Closed
1D price range
NT$40.37NT$40.72
52W price range
NT$24.62NT$42.28
YTD Perf.
+20.81%
YTD Flows
Annualized volatility
Fund AuM
€9.7M
Share class AuM
€9.7M
TTM Yield
-
Tracking Error
Tracking Difference
ISIN
TW0000067800
TER
1.01%
Inception date
1/16/2017
Replication method
Dividend policy
Compare similar ETFs
API
Performance
Flows
Join for free to unlock
Data as of 05/31/26
Healthcare
99.74%
Unavailable
0.25%
Latest 00678 news

No content available for this fund

FAQ about 00678

00678 is a Passive ETF. This ETF provides exposure to US Equities.
00678 tracks the NASDAQ Biotechnology Index - USD, through a full replication replication method.
00678 carries a total expense ratio (TER) of 1.01%, indicating the annual cost for holding the fund.
00678 was introduced to the market on January 16, 2017. It trades on Taiwan
CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF, 00678, is provided by Capital Investment Trust Corporation. Learn more about Capital Investment Trust Corporation here.
00678 oversees €9.7M in assets as of July 8, 2026.
00678 follows a capitalizing, meaning it reinvests income within the fund.
As of May 31, 2026, 00678 has significant geographic allocations in USA, United Kingdom and Netherlands.
As of May 31, 2026, 00678 focuses largely on Healthcare.
As of May 31, 2026, 00678 holds 253 positions in its portfolio, with 49.11% of assets concentrated in its top 15 holdings.
As of May 31, 2026, 00678 top three holdings include Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc. and Amgen, Inc..
The base currency of 00678 is TWD.
Data as of 05/31/26
Gilead Sciences, Inc.
7.38%
Vertex Pharmaceuticals, Inc.
7.36%
Amgen, Inc.
7.09%
Regeneron Pharmaceuticals, Inc.
5.07%
Alnylam Pharmaceuticals, Inc.
3.18%
Revolution Medicines, Inc.
2.48%
Biogen, Inc.
2.28%
Illumina, Inc.
1.98%
United Therapeutics Corp.
1.94%
Royalty Pharma Plc
1.90%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight